The Cancer Research Institute Associate Board is a group of young leaders dedicated to advancing cancer immunotherapy research. Members lend professional expertise and diverse talents to develop social events, assist with fundraising initiatives, and cultivate individual and corporate relationships.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
In February 2017, Oswald became one of the first patients to receive pembrolizumab (Keytruda®) as first-line therapy for non-small cell lung cancer.
Dr. Kunle Odunsi discusses genomic testing, new treatments, and promising clinical trials in immunotherapy for ovarian cancer.